ESWI Education Hub provides articles and links to important scientific papers, reviewed by the ESWI Board members, and other online educational activities
- Home
- Education hub
- Experts
Search experts on our site
I am a clinician-investigator with a passion for translational research in pediatrics and global health. My interest and research focus is respiratory syncytial virus (RSV) and maternal vaccination. My research has created an overview of vaccine development with an urgent message to make vaccines accessible in the developing world, where the majority of the children die. I aspire to work as a research-oriented clinician scientist in pursuit of an effective low-cost vaccine against RSV.
Dr Nathan Brendish is a NIHR Clinical Lecturer in Infectious Diseases & General Internal Medicine. His research interests focus on the clinical impact of point-of-care tests for infectious diseases.
Dr Brendish’s expertise in rapid diagnostic tests in severe respiratory virus infection stems from his PhD under Professor Tristan Clark at the University of Southampton. Dr Brendish continues to be part of Prof Clark’s research group.
Dr Brendish was the lead study fellow on the ResPOC trial. The ResPOC trial was a large, pragmatic, randomised controlled trial of routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness versus standard care. This showed that multiplex molecular testing at the point-of-care for respiratory viruses improved diagnosis of influenza, improved appropriate neuraminidase inhibitor prescribing, improved appropriate use of isolation facilities, and decreased length of hospital stay. This seminal study was published in The Lancet Respiratory Medicine in 2017.
Dr Brendish was also the lead fellow for the CoV-19POC trial of molecular point-of-care testing for SARS-CoV-2, which also showed multiple clinical benefits of ultra-rapid PCR testing, and was published in The Lancet Respiratory Medicine in 2020.
Dr Brendish started his research career as a study physician in the NIHR Southampton Clinical Research Facility, focussing on malaria vaccine trials.
Dr Nicole Tsang is currently a Post-doctoral Fellow in the School of Public Health, the University of Hong Kong. Nicole obtained her MPH with distinction and PhD in the University of Hong Kong. Her research work primarily focuses on the public health and epidemiological considerations in the control of epidemic and pandemic respiratory infections, including the vaccine effectiveness, vaccine side effects profiles, vaccine acceptance, impact of school-based vaccination programme, effective disease control and vaccination strategies in community settings, diagnostic test performance, and novel approaches for disease surveillance to inform situational awareness of evolving epidemics.
Nicole is involved in facilitating several postgraduate public health modules. She is an Associate Fellow of the Advanced Higher Education, and a member of the European Respiratory Society Clinical Practice Guidelines Methodology Network, and the European Society of Clinical Microbiology and Infectious Diseases Evidence Review Group.
Broadcaster, entrepreneur and human rights campaigner Norah Casey was formerly a Dragon in the popular television series Dragons’ Den and is a well-known radio and television personality. The 2nd Edition of her book Spark! was recently published by Penguin and her TEDx talks include The Cure for Grief and The Courage to leave (her own testimony of domestic violence). Her digital learning platform Planet Woman seeks to empower women, and much of her pro-bono work is devoted to mentoring female founders globally. She serves on the European Board for Vital Voices, established in 1997 by Hillary Rodham Clinton and U.S. Secretary of State Madeleine Albright. She is a founder of the London-based Women's Irish Network and is a member of The International Women's Forum. Norah is currently serving on the Irish government Forum on a Family Friendly and Inclusive Parliament.
A journalist and former nurse, her awards include: Woman of the Decade Award from the Women’s Economic Forum in Delhi; Ireland’s Philanthropist of the Year award; five times Publisher of the Year; and Veuve Clicquot Business Woman of the Year. Her work to highlight domestic violence was recognised with a Safe Ireland SÍLA Leadership Award and she received the 2019 Lord Mayor Of Dublin Award. She is an Honorary Fellow of the Royal College of Surgeons and received the Honorary Graduate Award for 2018 from BFEI.
As well as owning Harmonia Publishing Ltd, Norah is an experienced broadcaster and producer. She was the Ambassador for Dublin Honours Magdalenes and executive producer of the 2022 television documentaries Ireland’s Dirty Laundry. Her work can be viewed at norahcasey.com.
Norah’s business expertise is extensive having acquired and grown multiple business to multi-million euro global success stories, as well as a wide range of business investments in Ireland and internationally. She has mentored leading global business leaders, politicians and public figures. Her corporate expertise includes leadership, corporate teambuilding, mentorship, innovation and strategy.
Nationality: Finnish
Position: Clinical Lecturer and Adjunct Professor, Paediatrics and Adolescent Medicine, University of Turku
Research Fields: respiratory tract infections, especially acute otitis media
ESWI member since 2022
Dr. Tähtinen received her Doctor of Medicine from the University of Turku in 2004. After graduating, she worked as a GP and resident in paediatrics in Central Finland and then as a PhD student at the University of Turku. In 2012, she successfully defended her PhD thesis entitled “Treatment of acute otitis media”. The same year, she received the ESPID Young Investigator Award and was selected as a Researcher of the Year by the National Graduate School of Clinical Investigation. After obtaining her PhD degree, Dr. Tähtinen continued her specialisation in paediatrics at the Turku University Hospital, Department of Paediatrics and Adolescent Medicine.
In 2013-2015 and in 2017 Dr. Tähtinen moved to the United States to work as a Postdoctoral Research Fellow at the Boston University School of Medicine and Harvard T.H. Chan School of Public Health. During her time in Boston, Dr. Tähtinen also studied at the Harvard Medical School Global Clinical Scholars Research Training Program in which she graduated in 2015.
Currently, Paula Tähtinen is an Adjunct Professor and Clinical Lecturer at the University of Turku, Finland. She is also working as a paediatrician at Turku University Hospital. She is leading her own research group with the main focus on prevention and treatment of respiratory tract infections. Dr. Tähtinen has been actively involved in the development of scientific and professional education at the University of Turku. She has also served as a Young ESPID (European Society for Paediatric Infectious Diseases) country representative and a committee member at the ESPID Research Networking Committee. In 2022, Dr. Tähtinen received the Helena and Niilo Hallman Prize for the best young researcher in the field of paediatrics.
- Burden of disease in acute respiratory virus infections
- ESWI invites coalition partners: Life Course Immunisation: A Seamless Approach to Protection Across All Ages
- What is the difference between influenza and a common cold?
- Immunisation & Treatment - Societal benefits of immunising children
- Webinar: Immunisation & Treatment
- Respiratory tract infections in children - our paediatrician's insight and bold vision for the future
Nationality: British
Position: Respiratory physician and mucosal immunologist, Professor of Experimental Medicine, Imperial College, London
Research fields: Lung immunology, RSV, received a lifetime achievement in work on RSV research (Chanock prize, US, in 2012)
ESWI member since 2008
Peter Openshaw MD PhD CBE is Professor of Experimental Medicine at Imperial College London, UK. A respiratory physician and mucosal immunologist, his research focuses on how the immune response both protects against viral infection but also causes disease.
He has published widely on vaccinology, the immunopathogenesis of pulmonary viral diseases and lung inflammation. He is especially known for his work on respiratory syncytial virus (RSV), influenza and COVID-19, and for the development of human challenge in volunteers. He has co-authored over 400 publications and has an h-index of 105 (Google Scholar accessed Aug 2024). See also: https://orcid.org/0000-0002-7220-2555.
He was the first clinical President of the British Society for Immunology (2013-18) and served on many grant committees and Advisory Boards, becoming an Honorary Lifetime Member of the British Society for Immunology (2019). He has received prizes for his lifetime contribution to RSV research (Chanock Award, 2012), the European Federation of Immunological Societies Award (2014) and the Per Brandtzaeg Distinguished Scientific Achievement Award in mucosal immunology (2024).
He has built strong connections with journalists in print, radio and TV and used social media to promote accurate reporting of science stories, especially in relation to vaccines and respiratory disease. For example, he appeared over 100 times on national and international TV and radio between March 2021 and March 2022, explaining the complexities behind the COVID-19 pandemic response.
He advised the UK government on pandemics (SAGE, 2009-12; Chair/Vice-Chair of NERVTAG, 2015-2022). He was made a Commander of the British Empire for services to Medicine and Immunology in the 2022 UK New Year’s Honours and received the 2024 Imperial College Medal for his work as a Consul, supporting the development of the university’s Ethos, Values and Behaviours (Respect, Collaboration, Excellence, Integrity and Innovation).
- RSV - the bumpy road towards a vaccine
- Is RSV a serious illness?
- How can you tell the difference between RSV and other respiratory diseases, like COVID-19 or influenza?
- ESWI Respiratory Virus Summit 2024 recap video
- Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus
- ESWI Summit 2024: Conclusions
- Welcome By The Co-Chairs at the Respiratory Virus Summit 2024
- Immunisation & Treatment - New approaches to influenza prevention and treatment - lessons learnt from COVID- 19
- Webinar: Immunisation & Treatment
- ESWI Respiratory Virus Summit 2024
- ESWI Symposium: RSV Looking towards the future
- RSV looking towards the future
- Respiratory Virus Summit 2023
- “Flu, COVID and RSV: How to vaccinate?” symposium at Options XI
- A mucosal perspective on pandemics
- Using correlates to accelerate vaccinology
- RSV Disease in a COVID-19 era
Nationality: British
Position: Professor of Medical Virology and head of the influenza Centre
Research Fields: Development and evaluation of influenza vaccines, SARS CoV-2 long term complications
Short description:
Rebecca Cox is professor in medical virology and head of the Influenza Centre at the University of Bergen, Norway leading a team of scientists. Rebecca Cox completed her Ph.D. in 1995 at the London Hospital Medical College, University of London, UK before post doc positions at Guys Hospital, UK and the University of Bergen, Norway. She has >25 years of experience of influenza work particularly in development and evaluation of influenza vaccines. During the COVID-19 pandemic she led studies on SARS CoV-2 infection and vaccination and long term follow up of complications in Western Norway. She has served as advisor to the WHO SAGE Immunization Working Group on Influenza, the Norwegian epidemic and pandemic committee and European Medicines Agency (EMA). Her research focuses on development and evaluation of influenza vaccines with particular focus on human immune responses to infection and vaccination. She currently sits on the EMA Scientific working group on vaccines and the European Expert Group on SARS-CoV-2 variants. She is deputy chair of Influenza and Other Respiratory Viruses and senior editor for the journal Influenza and Other Respiratory Viruses. She is author of more than 100 peer-reviewed papers and regularly contributes to the public debate on Influenza, SARS CoV-2 and vaccines through multi-media channels.
Richard Webby is a Member of the Department of Infectious Diseases at St Jude Children’s Research Hospital and Director of the World Health Organization Collaborating Center for Studies on the Ecology of Influenza in Animals. He has a research program, funded by ALSAC, the fundraising arm of St Jude, and the US National Institutes of Health, that focuses on influenza viruses at the human-animal interface. This work involves virologic and serologic surveillance activities in animal and human populations to determine the prevalence of influenza viruses present.
Further laboratory-based research sets out to understand the mechanisms behind various viral phenotypes. His expertise is in influenza virology and he has substantial experience in vivo and in vitro models of influenza virus replication, pathogenicity, and transmission. Data collected through the above activities feeds into the WHO GISRS system for risk assessment of circulating influenza viruses and, where appropriate, subsequent pandemic preparedness activities such as candidate vaccine virus production and distribution.
Bio coming soon...
Robert A. Gabbay, MD, PhD, FACP, is the Chief Scientific and Medical Officer for the American Diabetes Association (ADA), the global authority on diabetes. Dr. Gabbay leads the ADA’s efforts to drive discovery within the world of diabetes research, care and prevention.
Previously, Dr. Gabbay served as the Chief Medical Officer and Senior Vice President at Joslin Diabetes Center, and Associate Professor at Harvard Medical School. At Joslin, he oversaw the clinical care for over 25,000 patients, as well as the education and care programs Joslin delivers nationally and internationally. His research focused on innovative models of diabetes care to enhance diabetes outcomes and improve the lives of people with diabetes. The reach of his work has been recognized through leadership roles in national and international activities to transform diabetes care.
Dr. Gabbay completed his B.Sc. Degree at McGill University and his PhD in Biochemistry from the University of Wisconsin where he published on mechanisms of insulin signaling. He then went on to get his medical degree from the State University of New York at Brooklyn School of Medicine with a residency in Internal Medicine at New York Hospital-Cornell and fellowship in Endocrinology, Diabetes and Metabolism at a joint Joslin-Beth Israel Deaconess-Brigham and Women’s Hospital program at Harvard. Dr. Gabbay was a visiting scientist at MIT and a Professor of Medicine at Pennsylvania State University College of Medicine and founding director of the Penn State Institute of Diabetes and Obesity before his tenure at Joslin.
Robert Steffen, Professor Emeritus at the University of Zurich was the Head of the Division of Communicable Diseases in the Epidemiology, Biostatistics and Prevention Institute and Director of a World Health Organization (WHO) Collaborating Centre for Traveller's Health. He also is Adjunct Professor at the University of Texas School of Public Health in Houston.
In the 1970’s he started systematic research in morbidity and mortality of illnesses and accidents related to international travel. Meanwhile he has (co-)authored over 400 publications, among them many relating to vaccination. He was the Editor-in-Chief of the Journal of Travel Medicine, of the International Journal of Public Health and Section Editor for Clinical Infectious Diseases. In the 27 years of his tenure at the Zurich University Center for Travel Medicine he supervised over 1 million vaccinations as in that travel clinic there were almost 20,000 consultations per year.
Robert Steffen presided the Swiss Federal Commission for Influenza; he was Vice- President both of the Federal Commission on Vaccination and of the Swiss Bioterrorism Committee. The WHO often has invited him to advisory boards, such as during the revision of the International Health Regulations (IHR). During the Ebola outbreaks in West Africa 2014-2016 and 2018-2020 in the DRC he served as Chair of the Ebola Emergency Committee.
Nationality: Czech
Position: Professor of Epidemiology, Charles University, Prague; and Chair, School of Public Health, Postgraduate Medical School, Prague
Research fields: Preventive medicine, clinical development of new vaccines (pneumococcus; rotavirus; measles, mumps, rubella (MMR); and human papillomavirus)
ESWI member since 2013
Professor Roman Prymula holds the position of Professor of Epidemiology at the Charles University in Prague, School of Medicine Hradec Kralove, Department of Preventive Medicine and Chair of the School of Public Health, Postgraduate Medical School Prague at the same time.
He received his medical degree from Charles University, Prague in 1988 and his PhD from Purkyne Military Medical Academy, Hradec Kralove in 1999. Prof. Prymula also studied at the University of Birmingham, UK, where he completed an International Certificate in Hospital management in 1995. In 1996 he became associate professor of epidemiology.
He has been involved in various research activities in preventive medicine, including clinical development of new vaccines, such as those for pneumococcus; rotavirus; measles, mumps, rubella (MMR); and human papillomavirus. In addition to his active research and teaching activities, he has served as a member of the European Centre for Disease Prevention and Control (ECDC) management board, Chairman of the Central European Vaccination Awareness Group, and Chairman of the Czech Vaccinological Society JEP.
Prof. Prymula is on the editorial board of several scientific journals and serves as a consultant for several national and international organisations. He is the former Minister of Health in the Czech Republic.
Nationality: Dutch
Position: Professor, Molecular Virology
Ron Fouchier is currently a professor in Molecular Virology at Erasmus MC Rotterdam, where he is also the deputy head of the Viroscience department. He obtained a PhD in 1995 for HIV/AIDS research at the University of Amsterdam with Hanneke Schuitemaker and Han Huisman and continued HIV work at the Howard Hughes Medical Institute, University of Pennsylvania School of Medicine as a postdoc with Michael Malim. Late 1998 he started a Molecular Virology research line on respiratory viruses, in particular influenza, at Erasmus MC.
Ron Fouchier’s team contributed substantially to the identification and characterization of various “new” viruses, such as human metapneumovirus, human coronavirus NL63, SARS coronavirus, MERS coronavirus, and influenza A virus subtype H16. Currently, his research is focused on respiratory viruses of humans and animals, antigenic drift, and influenza virus zoonoses, transmission and pandemics.
Ron Fouchier is elected member of the Royal Dutch Academy of Sciences (KNAW), the Royal Holland Society of Sciences and Humanities (KHMW) and Academia Europeae. In 2006 he received the Heine-Medin award of the European Society for Clinical Virology and in 2013 the Huibregtsen award for top innovative science with societal impact. Fouchier is a web-of-science Highly Cited author.
Roxana joined IFA as a project officer in 2022. She holds a Bachelor of Applied Science, specializing in Nutrition Science from Ryerson University, and is working towards a concurrent dual Master of Business Administration (MBA) and Master of Public Health (MPH). Roxana has been involved in many researchand policy-based projects in non-profit, governmental,and intergovernmental organizations, further developingher interests and skills concerning the social determinants of health, research, and health advocacy.
Roxana is experienced in the area of research, integrated with an empathetic driven mindset acquired from her professional experiences. She has worked in the Ministry for Seniors and Accessibility, supporting the program evaluation of the Seniors Active Living Centres, as well as has been directly involved in the development of the Trustworthy Artificial Intelligence Framework, supported by the Ontario Digital Service from the Ministry of Finance.
Ruth A. Karron, M.D.
Professor, International Health
Bloomberg School of Public Health
Joint Appointment, Pediatrics
School of Medicine
Johns Hopkins University
Dr. Karron is a pediatric infectious diseases physician, virologist, and vaccinologist, Professor in the Department of International Health at the Bloomberg School of Public Health, and Director of the Johns Hopkins Vaccine Initiative. Dr. Karron has substantial experience in the evaluation of respiratory virus vaccines in adult and pediatric populations. Her research interests also include the development of immune responses to respiratory viral infections in early life, the epidemiology of RSV and other respiratory viral diseases in low resource settings, and public policy and ethical issues related to vaccine development and distribution. Dr. Karron has been a member of a number of national and international vaccine advisory committees and panels, including the CDC Advisory Committee on Immunization Practices (ACIP) and the COVAX ACT-acclerator COVID Vaccine Maternal Immunization Working Group, and is a current member of the GAVI VIS Steering Committee. She has chaired the FDA Vaccine and Related Biological Products Advisory Committee (VRBPAC) and the Vaccines Advisory Panel for the Wellcome Trust, and currently chairs the WHO Product Development for Vaccines Advisory Committee (PDVAC). In 2016, Dr. Karron received the Robert M. Chanock award for outstanding lifetime contributions to RSV research.
- Studied German and English Literature in Switzerland and England.
- Diagnosed with T1 diabetes in 1973.
- Get certifications on Life and Diabetes Coaching and Family Counsellor.
- Worked as Peer to Peer project with Turkish Diabetes Foundation.
- Make programmes for Diabetes Living at Television.
- Make workshops for What are the expectations from the healthcare team as a person living with diabetes.
- Wrote three books about Diabetes.
- Members of Turkish Diabetes Foundation and Living with Diabetes Association.
- Doing television programme this year as well.
- Worked at Houston-Texas Methodist Hospital in International Department
Seema Lakdawala is an Associate Professor in the Microbiology and Immunology Department at the Emory School of Medicine. Her lab studies epidemiological success of influenza A viruses to better predict future pandemics. Specifically, Lakdawala Lab is interested in intracellular assembly of influenza viruses and person-to-person transmission of viruses. They combine biochemistry and sophisticated microscopy tools to define where, when and how assembly of influenza genomic RNA occurs. This research has broad implications for understanding the reassortment potential of circulating animal influenza viruses and may lead to the development of new antiviral targets.
In addition, airborne transmission of influenza viruses is critical for rapid spread of the virus during epidemics and pandemics. They have established a method to study the viability of influenza viruses in expelled aerosols and droplets at different environmental conditions, as well as the airborne transmissibility of influenza viruses in the ferret model. These studies will define the viral and environmental properties that promote the spread of influenza. Combining these two areas of research, they will be able to develop a comprehensive surveillance system to determine the pandemic potential of circulating zoonotic influenza viruses, which will be useful in all areas of pandemic preparedness.
BSc (Hons), MBBS, FRCPCH, PhD, PgDip PID (Oxford)
I am a consultant and clinical lead in paediatric infectious diseases and immunology at St George’s University Hospitals NHS Foundation Trust, London, UK and an honorary senior lecturer at St George’s, University of London (SGUL). I lead the St George’s congenital infection clinic, am the hospital’s paediatric antimicrobial stewardship lead and am the South-West London lead for post-COVID19 syndrome. I am the chief examiner for penultimate year medical students at SGUL and teach on multiple undergraduate and postgraduate courses in SGUL and externally. I am the Royal College of Paediatrics and Child Health (RCPCH) paediatric immunology and infectious diseases college specialty advisory committee (CSAC) training advisor. I also work as a member of several large European collaborative research studies, and act as chief and principal investigator on multiple clinical trials investigating diagnostics, novel treatments, and prophylactics for a variety of infectious conditions. My main research interests are perinatal infections, antimicrobial resistance and stewardship and epidemiology, management and prevention and host susceptibility to respiratory syncytial virus (RSV) and other respiratory viral infections. I also sit on multiple local, national, and international committees related to paediatrics including the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) RSV subcommittee and the Medicines and Healthcare products Regulatory Agency’s (MHRA) Paediatric Medicine Expert Advisory Group (PMEAG).
Professor Sir Andrew Pollard BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FMedSci
Ashall Professor of Infection and Immunity
Sir Andrew is Director of the Oxford Vaccine Group at the University of Oxford and an honorary consultant paediatrician (infectious disease and immunology) at Oxford Children’s Hospital. He received a knighthood in the Queen’s Birthday Honours in 2021 for services to Public Health and the Order of Medical Merit from the Federal Republic of Brazil in 2022.
His research includes the design, development and clinical evaluation of vaccines including those for typhoid, meningococcus, Haemophilus influenzae type b, pneumococcus, plague, pertussis, influenza, rabies, coronavirus and Ebola. His work on pneumococcal and meningococcal vaccines has been used in global public health policy. His studies on typhoid both using the human challenge model and in field sites supported the WHO prequalification of a new typhoid conjugate vaccine and WHO recommendations for its use in countries with a high burden of disease with more than 50 million vaccinated since 2021. He was the chief investigator for the clinical trials of the Oxford-AstraZeneca vaccine in 2020 in 24,000 participants in UK, South Africa and Brazil, which led to authorisation of the vaccine for use in more than 180 countries with over 3 billion doses distributed and award of the Copley Medal by the Royal Society in 2022. He has supervised 50 PhD students and his publications includes over 700 manuscripts. He chairs the UK Department of Health and Social Care’s Joint Committee on Vaccination and Immunisation, and was a member of WHO’s Strategic Advisory Group of Experts (2016-2022). He chaired the European Medicines Agency scientific advisory group on vaccines (2012–2020). He received the Bill Marshall Award of the European Society for Paediatric Infectious Disease (ESPID) in 2013, the ESPID Distinguished Award for Education and Communication in 2015 and the Rosén von Rosenstein medal in 2019 from the Swedish Society of Medicine, the James Spence Medal from the Royal College of Paediatrics and Child Health in 2022. He is chair of the Knoop Charitable Trust and is a trustee of the Jenner Vaccine Foundation, the Academy of Medical Sciences and the Oxford Philharmonic Orchestra.
Solvejg Wallyn is policy coordinator International Health issues at the Flanders Agency for Care and Health. Her primary concern is to ensure that the health and care policy development in Flanders will benefit from bilateral and international exchanges. As policy coordinator she works closely together with the Regions for Health Network of WHO Europe, the European Network for Regional and Local Health Authorities. She is also responsible for the follow up of the work of the EU Commission and Working Groups of the Council.
Stacey Schultz-Cherry, PhD, is a Member (Professor) in the Department of Host-Microbe Interactions at St Jude Children’s Research Hospital in Memphis, TN as well as Senior Associate Dean for Academic Affairs in the St Jude Graduate School of the Biomedical Sciences. She serves as Co-Director of not only the Center for Excellence in Influenza Research and Response but also the Collaborative Influenza Vaccine Innovation Center, both research centers supported by the National Institute of Allergy and Infectious Diseases.
Dr. Schultz-Cherry received her PhD in Molecular and Cellular Pathology from the University of Alabama at Birmingham investigating extracellular matrix and growth factor interactions. After a short postdoctoral fellowship at the University of Wisconsin-Madison studying influenza virus- induced apoptosis and cellular responses, she served as a Lead Scientist at the U.S. Department of Agriculture Southeast Poultry Research Laboratory in Athens, GA, doing research on emerging highly pathogenic avian influenza viruses and astroviruses. She subsequently joined the faculty in the Department of Medical Microbiology and Immunology at the University of Wisconsin, Madison Medical School rising to become tenured Associate Professor before moving to St Jude Children’s Research Hospital in 2009.
Dr. Schultz-Cherry is recognized internationally for her studies on the pathogenesis of influenza and enteric viruses, especially astroviruses, in high-risk populations, and on the interactions of influenza viruses among different avian species and other animals and humans. She is the author and co-author of over 250 research articles, reviews, and book chapters and has lectured internationally. She has been a member of the editorial boards of several prominent journals and is now the editor-in-chief of the Journal of Virology.
Dr. Schultz-Cherry has served on the National Institutes of Health study sections and other of its institutional committees. She was elected President of the American Society for Virology in 2017, is the current chair of the Public and Scientific Affairs Committee for the American Society for Microbiology and is an American Academy of Microbiology Fellow. Since 2012 she has been Deputy Director of the World Health Organization Collaborating Center for Studies on the Ecology of Influenza in Animals and Birds.
A geriatrician, former John Franklin Chair of Geriatrics and Director of the Glennan Center for Geriatrics and Gerontology at Eastern Virginia Medical School (1996-2007), and Director of Center for Geriatrics and Palliative Care at University Hospitals in Cleveland (2014-2017), he is now the David S. Greer Professor of Geriatrics and Professor in the departments of Medicine and Health Services Policy and Practice at Brown's schools of medicine and public health. He serves as the Director, Division of Geriatrics and Palliative Medicine at the Alpert Medical School of Brown University and Associate Director of the Center on Innovation in Long-Term Services and Supports at the Providence Veterans Administration Medical Center. Dr. Gravenstein has a long-standing interest in immunity, inflammation, cardiovascular outcomes and aging especially in the context of vaccines and the long-term care setting, and the topic of the majority of his publications. He also has a specific interest in quality improvement in health care, the culture of care, antimicrobial stewardship, and how to improve care transitions. Beginning in 2020, he became active in several projects related to COVID in long-term care. He was Clinical Director at Healthcentric Advisors, Medicare's Quality Improvement Organization for New England from 2007 to 2019.
Nationality: Italian
Position: Research Director, CNR Ageing Branch, Neuroscience Institute, Padova (Italy)
Research Fields: Clinical epidemiology and geriatrics. Main focus on lifelong approach to healthy ageing
ESWI member since 2022
Dr. Stefania Maggi received her degree in Medicine and Surgery from the University of Padua, Italy in 1983. She also attended the Graduate School of Geriatrics and Gerontology from the same University until 1987 and in 1988 she received her Master in Public Health from John Hopkins University in Baltimore (USA). Dr. Maggi also holds a PhD in Clinical Pathophysiology from the University of Padua, which she received in 2000.
Dr. Maggi has a specific interest in the epidemiology of ageing and in the analysis of factors promoting health ageing in a lifelong approach. From 1983-1985, Dr. Maggi worked as an attending physician at the Internal Medicine Department for the University Hospital in Padua before she spent the years of 1988-1989 as a postdoctoral fellow at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), for the National Institute of Health (NIH) in Bethesda, Maryland (USA). From 1989-1993, she worked as the Coordinator for the WHO Program on Ageing, before she moved on to work as a researcher in the Ageing branch at the Institute of Neuroscience, Consiglio Nazionale Delle Ricerche (CNR), Padua. Dr. Maggi worked as a researcher from 1993-2007 before becoming Research Director for the same branch and institute, in 2007, a position she currently holds. In this position, she coordinates several national and international research projects on nutrition, vaccines and lifestyle as key factors for promoting healthy ageing. Dr. Maggi is also an Adjunct Professor in the Graduate Schools of Geriatric Medicine at the University of Padua, which she has been since 2000.
Moreover, Dr. Maggi is the Editor in Chief of “Ageing Clinical and Experimental Research” (Springer) and has more than 800 publications, both in peer-reviewed journals and many book chapters.
- Europe needs a Life Course Immunisation Strategy
- ESWI invites coalition partners: Life Course Immunisation: A Seamless Approach to Protection Across All Ages
- Association between vaccinations and risk of dementia: a systematic review and meta-analysis
- Burden of disease in acute respiratory virus infections
- ESWI invites coalition partners: Life Course Immunisation: A Seamless Approach to Protection Across All Ages
- RSV - the bumpy road towards a vaccine
- Will individuals need an annual COVID-19 vaccination?
- What are the risks of RSV infections for older individuals?
- ESWI Respiratory Virus Summit 2024 recap video
- Welcome By The Co-Chairs at the Respiratory Virus Summit 2024
- Burden of acute respiratory virus infections
- ESWI Respiratory Virus Summit 2024
- Communication: Raising awareness on the burden of disease
- ESWI Symposium: RSV Looking towards the future
- Burden of disease - A focus on acute respiratory viruses in older adults
- RSV looking towards the future
- Respiratory Virus Summit 2023
- A geriatrician's insight into reducing the burden of disease in older adults
Sue is a highly-experienced TV news journalist with a specialism in medical matters. She was Medical Correspondent at ITV News for many years and now freelances for national news, alongside chairing conferences and medical symposia, hosting awards events, running media and PR training, consulting to the pharmaceutical industry and making corporate films.